These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 7831657

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
    Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P.
    Lancet; 1996 Mar 09; 347(9002):635-9. PubMed ID: 8596376
    [Abstract] [Full Text] [Related]

  • 7. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery.
    Agnelli G, Sonaglia F.
    Semin Thromb Hemost; 1997 Mar 09; 23(2):143-8. PubMed ID: 9200338
    [Abstract] [Full Text] [Related]

  • 8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV, Howes J, Sharma V, Kadziola Z.
    Thromb Haemost; 2000 Apr 09; 83(4):523-9. PubMed ID: 10780310
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P.
    J Am Coll Cardiol; 1993 Oct 09; 22(4):1080-8. PubMed ID: 8409044
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU, Haas S, Maurer R, Lassmann A, Dübbers K, Müller-Peltzer H.
    Thromb Haemost; 1997 May 09; 77(5):911-9. PubMed ID: 9184402
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G, Hoffmann U, Hoffmann I, Harenberg J, Heene DL.
    Dtsch Med Wochenschr; 2000 Jun 02; 125(22):686-91. PubMed ID: 10874895
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug 02; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP.
    Thromb Haemost; 1994 May 02; 71(5):558-62. PubMed ID: 8091380
    [Abstract] [Full Text] [Related]

  • 18. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD, EXPERT Study Group.
    Thromb Haemost; 2009 Jan 02; 101(1):68-76. PubMed ID: 19132191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P.
    Thromb Res; 2007 Jan 02; 120(5):685-93. PubMed ID: 17292948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.